A dose-finding trial evaluating the efficacy and safety of three different doses of recombinant hirudin, CGP 39393 (Revasc-Ciba), in patients undergoing total hip replacement - Eriksson, B I; Kalebo, P; Ekman, S; Baur, M; Bach, D; Kerry, R; Close, P (Thromb Haemost, 1995)